{"disease":{"id":"generalized-pustular-psoriasis","name":"Generalized pustular psoriasis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":4},"drugs":{"marketed":[{"drug_id":"spesolimab","indication_name":"Generalized pustular psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Spevigo","generic_name":"SPESOLIMAB","company_name":"Boehringer Ingelheim Pharmaceuticals Inc","drug_phase":"marketed","molecular_target":"Interleukin-1 receptor-like 2","drug_class":"Interleukin-36 Receptor Antagonist [EPC]","quality_score":62,"revenue":"300","mechanism":"Spevigo works by blocking the interleukin-36 receptor, which plays a key role in the development of psoriasis symptoms."},{"drug_id":"spesolimab-sbzo","indication_name":"Generalized pustular psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"SPEVIGO","generic_name":"SPESOLIMAB-SBZO","company_name":"BOEHRINGER INGELHEIM PHARMACEUTICALS INC","drug_phase":"marketed","molecular_target":"Interleukin-1 receptor-like 2","drug_class":"Interleukin-36 Receptor Antagonist [EPC]","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe generalized pustular psoriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chronic-pf-06480605-450-mg-sc-q4w","indication_name":"Moderate to severe generalized pustular psoriasis in infants and children","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chronic- PF-06480605 450 mg SC Q4W","generic_name":"chronic-pf-06480605-450-mg-sc-q4w","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"IL-4 receptor alpha subunit","drug_class":"pharmacological class not specified","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04566471","title":"Palmoplantar Pustulosis and Generalized Pustular Psoriasis: A National Population-based Analysis of Prevalence","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT03886246","title":"Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":131,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT03051217","title":"A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":127,"lead_sponsor_name":"UCB Biopharma S.P.R.L.","has_results":true},{"nct_id":"NCT04399837","title":"A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":123,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT06391996","title":"Biologic Therapy for Generalized Pustular Psoriasis","phase":"","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Chao Ji","has_results":false},{"nct_id":"NCT03782792","title":"Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":53,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT05670821","title":"PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms","phase":"","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT05352893","title":"Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Vanda Pharmaceuticals","has_results":true},{"nct_id":"NCT06013969","title":"A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":42,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT05366855","title":"Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":42,"lead_sponsor_name":"Vanda Pharmaceuticals","has_results":true},{"nct_id":"NCT05239039","title":"An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT06477536","title":"Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":33,"lead_sponsor_name":"Shanghai Huaota Biopharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06231381","title":"Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":33,"lead_sponsor_name":"Shanghai Huaota Biopharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06295692","title":"A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":19,"lead_sponsor_name":"Janssen Pharmaceutical K.K.","has_results":true},{"nct_id":"NCT06323356","title":"A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":18,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT07428915","title":"Evaluating Legit.Health Plus Support for Improving Diagnosis of Generalized Pustular Psoriasis and Other Skin Conditions Among Primary Care Physicians and Dermatologists","phase":"","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"AI Labs Group S.L","has_results":false},{"nct_id":"NCT03942042","title":"A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT05200247","title":"An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT02533375","title":"Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT05512598","title":"HB0034 in Patients With Generalized Pustular Psoriasis (GPP)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Shanghai Huaota Biopharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03619902","title":"A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Vanda Pharmaceuticals","has_results":true},{"nct_id":"NCT06886009","title":"Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false}],"total":22},"guidelines":[],"source":"Drug Landscape verified database"}